Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina by Ottervanger, J.P. (Jan Paul) et al.
ISSN: 1524-4539 
Copyright © 2003 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online
72514
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX
DOI: 10.1161/01.CIR.0000046487.06811.5E 
 2003;107;437-442; originally published online Jan 6, 2003; Circulation
Investigators 
Ohman, S. James, E. Topol, L. Wallentin, M.L. Simoons and for the GUSTO IV-ACS 
J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M.
 Syndrome) Trial
Strategies To Open Occluded Coronary Arteries IV—Acute Coronary
Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of 
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in
 http://circ.ahajournals.org/cgi/content/full/107/3/437
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/static/html/reprints.html
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email: 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden
  
 http://circ.ahajournals.org/subsriptions/
Subscriptions: Information about subscribing to Circulation is online at 
 at SWETS SUBS SERVICE on October 11, 2006 circ.ahajournals.orgDownloaded from 
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor
Abciximab in Unstable Angina
One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To
Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial
J.P. Ottervanger, MD; P. Armstrong, MD; E.S. Barnathan, MD; E. Boersma, PhD; J.S. Cooper, MS;
E.M. Ohman, MD; S. James, MD; E. Topol, MD; L. Wallentin, MD; M.L. Simoons, MD; for the
GUSTO IV-ACS Investigators
Background—This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in
patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention.
Methods and Results—A total of 7800 patients were included with an acute coronary syndrome without ST elevation,
documented by either elevated cardiac troponin or transient or persistent ST-segment depression. They were randomized
to abciximab bolus and 24-hour infusion, abciximab bolus and 48-hour infusion, or matching placebo. The overall
1-year mortality rate was 8.3% (649 patients). One-year mortality was 7.8% in the placebo group and 8.2% in the
24-hour and 9.0% in the 48-hour abciximab infusion group. Compared with placebo, the hazard ratio for the 24-hour
infusion of abciximab was 1.1 (95% CI 0.86 to 1.29), and for the 48-hour infusion, it was 1.2 (95% CI 0.95 to 1.41).
The lack of benefit of abciximab was observed in every subgroup studied. Patients with negative troponin or elevated
C-reactive protein had a higher mortality rate after treatment with abciximab for 48 hours than with placebo: 8.5%
versus 5.8% in those with negative troponin (P0.02), 16.3% versus 12.1% in those with elevated C-reactive protein
(P0.04).
Conclusions—Compared with placebo, abciximab did not provide any survival benefit at 1 year in patients admitted with
an acute coronary syndrome with ST depression and/or elevated troponin who were not scheduled to undergo early
coronary revascularization. In subgroups of patients, in particular those with low cardiac troponin or elevated C-reactive
protein, abciximab was associated with excess mortality. (Circulation. 2003;107:437-442.)
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The initiating event of an acute coronary syndrome (ACS)is thought to be rupture or erosion of an atherosclerotic
plaque in a coronary artery due to inflammation followed by
thrombosis.1 Of the patients who present with ACS without
ST-segment elevation, as many as 10% to 15% develop acute
myocardial infarction or death within 1 year after admission.
Medical therapy includes -blockers, nitrates, calcium chan-
nel blockers, and antithrombotic therapy: aspirin, heparin,
IIb/IIIa inhibitors, and clopidogrel.2–4 Coronary revascular-
ization by either PTCA or CABG can be considered and is
recommended in high- and intermediate-risk patients.2,3
There are several randomized studies about the use of
glycoprotein (GP) IIb/IIIa inhibitors in the treatment of
ACS.5–9 Beneficial effects of GP IIb/IIIa inhibitors in patients
with ACS have been demonstrated with abciximab in patients
with refractory angina who subsequently underwent a percu-
taneous coronary intervention (PCI)5 and with eptifibatide6
and tirofiban7 in studies in which a proportion of patients
underwent early revascularization. In contrast, after 30 days
of follow-up in the GUSTO IV-ACS (Global Use of Strate-
gies To Open Occluded Coronary Arteries IV—Acute Coro-
nary Syndrome) study, no benefit was observed with abcix-
imab8 in patients who where not scheduled for early coronary
revascularization. A recent meta-analysis of all major trials of
IIb/IIIa inhibitors in ACS, including GUSTO IV-ACS, dem-
onstrated a modest but significant (relative risk [RR] 0.91,
95% CI 0.85 to 0.98) reduction in death and myocardial
infarction at 30 days.10 The greatest benefit was observed in
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patients with elevated troponin, although data on troponin
levels were missing in many patients in those trials. In most
studies, follow-up data were available at 30 days and 6
months. In this report, we present the 1-year follow-up data of
7800 patients in GUSTO IV-ACS and relate these outcomes
to baseline characteristics, including concentrations of car-
diac troponin and C-reactive protein (CRP) at enrollment.
Methods
Study Design and Study Population
Design, methods, and 30-day main results of GUSTO IV-ACS have
been described previously.8 In short, it was a multicenter, interna-
tional, randomized trial of patients with ACS without persistent
ST-segment elevation, including non–ST-elevation myocardial in-
farction and unstable angina. Eligible patients were aged 21 years or
older and should have had 1 or more episodes of angina lasting at
least 5 minutes within 24 hours before admission. They had either an
abnormal cardiac troponin T or I test or at least 0.5 mm of transient
or persistent ST-segment depression.
Drug Regimen
Patients were randomly assigned to 1 of 3 treatment groups:
abciximab for 24 hours (0.25 mg/kg bolus followed by a 0.125-g ·
kg1 · min1 infusion up to a maximum of 10 g/min for 24 hours),
followed by 24 hours of placebo infusion; abciximab for 48 hours
(same bolus and infusion for total duration of 48 hours); or matching
placebo (bolus and 48-hour infusion). All patients were to receive
aspirin for at least 30 days if not contraindicated. Furthermore, all
patients received an unfractionated heparin bolus and infusion of
low-molecular-weight heparin (dalteparin) subcutaneously every 12
hours for 5 to 7 days or until a revascularization procedure or
discharge. Coronary angiography was not recommended during or
within 12 hours after completion of the study-agent infusion (ie,
within 60 hours after randomization) unless the patient had recurrent
or continuing ischemia at rest associated with ischemic ST-T
changes that were unresponsive to intensive medical therapy.
Blood Sampling
Venous blood samples were collected at baseline and 8, 16, 24, 36,
and 48 hours after randomization. Levels of CRP were determined at
baseline. An elevated CRP was defined as a CRP value 10 mg/L.
Elevated troponin was defined as cardiac troponin T or I above the
upper limit of normal for the local qualitative or quantitative assay.
Quantitative levels of troponin T were also determined centrally by
a third-generation assay on an Elecsys (Roche Diagnostics), with the
detection limit 0.01 g/L.
Follow-Up Evaluation and End Points
The primary end point in the trial was the occurrence, within 30 days
after randomization, of death (of any cause) or myocardial infarction,
adjudicated by the Clinical End Point Committee. Follow-up data
were obtained on vital status up to 1 year after randomization and
were completed for 7746 patients (99.3%). Deaths were reported by
the investigator at each site. Follow-up data were collected via the
register office, the general practitioner, or direct contact with patients
or their relatives by telephone.
Statistical Analysis
All analyses were by intention to treat. Differences between group
means were tested by 2-tailed Student’s t test. A 2 statistic was
calculated to test differences between proportions. Survival functions
were calculated with the Kaplan-Meier product limit method.11 Mantel-
Cox (or log-rank) test was applied to evaluate differences between
survival functions. Categories for subgroup analyses included age, sex,
diabetes, elevated troponin, ST depression, and CRP status. The effects
of troponin on survival were assessed on both the local (qualitative)
values and the central measured quantitative values. Quantitative tropo-
nin values were divided into quartiles. Statistical significance was
defined as a probability value of less than 0.05.
Results
Baseline Characteristics
Between July 17, 1998, and April 21, 2000, a total of 7800
patients were randomized. All baseline characteristics were
similar among the 3 treatment groups (Table 1). Centrally
measured quantitative troponin T levels ranged from 0.01 to
17.3 g/L, and quartile limits were 0.01, 0.12, and 0.47 g/L.
One-Year Mortality
Total mortality was 6.6% (516 patients) after 6 months and
8.3% (649 patients) after 1 year. Mortality was not signifi-
cantly different between the 3 treatment groups: 1-year
mortality was 7.8% in the placebo group, 8.2% in the 24-hour
abciximab-infusion group, and 9.0% in the 48-hour
abciximab-infusion group (Figure 1). Compared with pla-
cebo, the hazard ratio for the 24-hour infusion of abciximab
was 1.1 (95% CI 0.86 to 1.29), and for the 48-hour infusion
of abciximab, it was 1.2 (95% CI 0.95 to 1.41). When all
patients treated with abciximab (both 24 and 48 hours) were
compared with those treated with placebo, the hazard ratio
was 1.1 (95% CI 0.94 to 1.29).
Predictors of Mortality
Increasing age and diabetes were strong predictors of 1-year
mortality. Patients with body weight 75 kg had 1-year
mortality of 9.6% compared with 7.4% in patients with body
weight 75 to 90 kg and 6.6% in patients with weight 90 kg
(P0.001). The 1104 patients who were included in North
America had 1-year mortality of 9.1% compared with 8.8%
of those included in Eastern Europe and 7.9% of those
included in Western Europe (P0.28). Of the 4041 patients
with positive local measurement of troponin at baseline,
1-year mortality was 9.1% (369 patients) compared with
6.9% in patients with negative troponin at baseline
(P0.001). There was a gradual increase of 1-year mortality
with an increase in the quantitative troponin level: 1-year
mortality in the ascending quartiles of troponin was 3.8%,
TABLE 1. Baseline Characteristics
Characteristic
Placebo
(n2598)
24-h Abciximab
(n2590)
48-h Abciximab
(n2612)
Men 1609 (62) 1594 (62) 1667 (64)
Age, y 65.2 (11.1) 65.1 (11.3) 65.3 (11.5)
Previous MI 788 (30) 796 (31) 830 (32)
Diabetes 562 (22) 551 (21) 564 (22)
ST depression 2073 (80) 2094 (81) 2082 (80)
Raised troponin* 1329 (58) 1361 (60) 1351 (59)
Both ST depression and
raised troponin
815 (31) 875 (34) 823 (32)
Elevated CRP† 580 (22) 582 (22) 545 (21)
Both CRP and raised troponin 334 (13) 339 (13) 318 (12)
Values are n (%), except for age, which is mean (SD).
*Cardiac troponin T or I above the upper limit of normal for local qualitative
or quantitative assay.
†CRP value 10 mg/L.
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7.7%, 8.8%, and 13.3%, respectively. Of the 1707 patients
with elevated CRP, 1-year mortality was 13.9% (237 pa-
tients) compared with 6.5% in patients without elevated CRP
(P0.001). Although positive troponin was a stronger pre-
dictor of mortality than an elevated CRP level, both determi-
nants had independent additional value in predicting 1-year
survival.
Effects of Abciximab in Subgroups
In Figure 2, the association between treatment with placebo,
24-hour abciximab, or 48-hour abciximab and 1-year mortal-
ity according to several subgroups is summarized. There was
no subgroup in which patients treated with abciximab had
significantly lower 1-year mortality compared with placebo.
However, there were 3 subgroups in which 48-hour infusion
of abciximab was associated with increased 1-year mortality:
patients with body weight 75 kg and those with negative
troponin or positive CRP at baseline. In patients with elevated
troponin, an early mortality benefit was suggested for 24-hour
abciximab; however, the survival curves of all 3 treatment
groups with elevated troponin overlapped beyond 5 months
(Figure 3). In contrast, a gradient with better outcome in the
placebo group and worse outcome with 48-hour abciximab
was apparent throughout in patients with a negative troponin
value (Figure 4, log-rank test 0.04, P for trend0.02). In the
2842 patients without elevated troponin, 1-year mortality was
5.8% in the placebo group compared with 8.5% in the
48-hour infusion group (hazard ratio 1.5, 95% CI 1.1 to 2.1).
This effect was particularly apparent in females with negative
troponin (hazard ratio 1.7, 95% CI 1.0 to 3.0) and was less
clear in men (hazard ratio 1.4, 95% CI 0.9 to 2.1). In none of
the quantitative troponin quartiles was a significant difference
between the 3 treatment groups found. A consistent pattern of
increased mortality with 48-hour abciximab compared with
24-hour abciximab and placebo was also apparent in patients
with elevated CRP (log-rank test 0.1, P for trend0.04),
whereas mortality was low and event curves overlapped in
patients with a low CRP level at enrollment (Figure 5). In
patients with an elevated CRP level, 1-year mortality was
12.1% in the placebo group compared with 16.3% in the
48-hour infusion group (hazard ratio 1.4, 95% CI 1.0 to 2.0).
A total of 128 patients (1.6%) had percutaneous revascu-
larization within 48 hours, whereas 1509 patients had PCI
within 30 days. In patients undergoing PCI within 30 days,
there was no significant difference in the 1-year mortality rate
among the 3 treatment groups, although there was a nonsig-
nificant trend favoring abciximab therapy: 4.2% in the
placebo group, 3.8% in the 24-hour abciximab group, and
3.6% in the 48-hour abciximab group (P for trend0.6).
Discussion
The main findings at 1-year follow-up in GUSTO IV-ACS
were that in patients with ACS who are not scheduled for
early revascularization, routine use of abciximab did not
provide a survival benefit. In some subgroups, a statistically
significant excess mortality was apparent with 48-hour ab-
ciximab infusion, particularly in patients with elevated CRP,
normal cardiac troponin, and low body weight. The results
extend the previously reported findings of the primary and
secondary end points at 30 days.8
Figure 1. Proportion of patients who survived up to 1 year after
randomization to placebo, 24-hour infusion of abciximab, and
48-hour abciximab. There was no significant difference between
the 3 groups (P0.32).
Figure 2. Subgroup analysis of 1-year mortality, hazard ratio,
and 95% CI: placebo vs 24-hour abciximab, OO; placebo vs
48-hour abciximab, O‹O.
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Comparison With Previous Trials
The lack of mortality benefit at 1 year with prolonged
administration of abciximab in patients not undergoing early
revascularization is in contrast with the survival benefit
reported at follow-up of 5154 patients receiving abciximab
during and after PCI.12 In that meta-analysis, mortality after
an average follow-up of 1 year was 3.4% with abciximab and
4.3% with placebo (P0.031). The trend in patients under-
going PCI within 30 days in GUSTO IV-ACS was similar,
although not statistically significant. The interpretation of the
latter observation remains uncertain, however, because it was
not recorded whether patients received a GP IIb/IIIa inhibitor
at the time of the PCI. Studies with other GP IIb/IIIa
inhibitors in ACS also showed no survival benefit after a
follow-up period of 6 months,13 although GUSTO IV-ACS is
the only one of these trials in which the estimate of the
treatment effect favored placebo. The higher mortality in the
several subgroups in GUSTO IV-ACS after 48-hour abcix-
imab infusion are not fully explained. These subgroups may
provide insight into effects of abciximab separate from
platelet inhibition, as will be discussed below, but they may
also be chance findings, particularly since the overall findings
in the trial were not significantly different among the treat-
ment groups.
Excess Mortality in Subgroups
In GUSTO IV-ACS, an excess in mortality with abciximab
was observed in patients with negative cardiac troponin
levels, and an unfavorable trend was seen in patients with
signs of inflammation at enrollment, as reflected by elevated
CRP levels. Elevated troponin may be a marker of extended
intracoronary thrombosis in many patients, and without such
thrombosis, aggressive platelet inhibition may be less impor-
tant, and negative effects of antiplatelet therapy in general or
abciximab in particular may prevail. The association of
elevated CRP at enrollment and impaired outcome with
prolonged (48 hours) administration of abciximab suggests
that this particular GP IIb/IIIa receptor blocker may interfere
with and enhance an inflammatory response in a subgroup of
patients.
There is some evidence that GP IIb/IIIa inhibitors may,
under certain circumstances, increase the incidence of ad-
Figure 3. Proportion of patients (pts; n4041) with positive local
troponin who survived up to 1 year after randomization to either
placebo, 24-hour infusion of abciximab, or 48-hour abciximab.
Figure 4. Proportion of patients (pts; n2842) with negative
local troponin who survived up to 1 year after randomization to
either placebo, 24-hour infusion of abciximab, or 48-hour
abciximab.
Figure 5. Proportion of patients with either elevated or normal
CRP randomized to placebo, 24-hour abciximab, or 48-hour
abciximab.
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verse events. The long-term oral GP IIb/IIIa inhibitors did
increase mortality.14 Furthermore, there are some biological
explanations for untoward effects15: antagonist-induced plate-
let activation, insufficient level of platelet inhibition, and
proinflammatory effects. That the excess of mortality was
particularly observed in patients with 48-hour abciximab may
be explained by low levels of platelet inhibition during the
later parts of the infusion.
During PCIs, abciximab reduced the number of leukocyte-
platelet aggregates,16 and it diminished the rise in inflamma-
tory markers after PCI.17 However, it is possible that these
effects were secondary to the antithrombotic effects of
abciximab. It has also been shown that abciximab may
enhance leukocyte adhesion18 and that low dosages of abcix-
imab may cause platelet activation and shedding of CD40
ligants.15 These may be interpreted as proinflammatory ef-
fects. Accordingly, the clinical importance of the effects of
abciximab on inflammation, and the duration of these effects,
should be further investigated.
Differences in Design Between Previous Trials
In the first report of GUSTO IV-ACS8 and the accompanying
commentary,19 several suggestions were made for design-related
causes of the unexpected lack of benefit with abciximab as
observed: the patient selection, the dose and duration of abcix-
imab, and statistical issues.8 None of these appeared to be fully
satisfactory.19 The new information presented in this 1-year
follow-up report indicates that the lack of benefit with abciximab
is authentic and is not due to statistical chance.
An important difference from most previous studies of GP
IIb/IIIa inhibitors in unstable angina was that in GUSTO
IV-ACS, early angiography and subsequent revascularization
were discouraged. Benefits of inhibition of platelet aggrega-
tion with abciximab and other GP IIb/IIIa receptor blockers
have been demonstrated particularly in patients undergoing
percutaneous (balloon or stent) coronary intervention.5,20–25
In this setting, disruption at the arterial wall may result in
extensive intracoronary thrombosis, which can be prevented
to a large extent by intensive antiplatelet therapy. In GUSTO
IV-ACS, revascularization was performed within 48 hours in
only a very few patients (0.3% CABG, 1.6% PCI), and
abciximab would have been of particular benefit in these
patients.8 Furthermore, of the 36 patients in the placebo group
who underwent PCI within 48 hours, 24 (66%) received
abciximab (leaving only 12 patients with PCI within 48 hours
on placebo, without abciximab), which may have masked
potential beneficial effects of abciximab versus placebo. The
observed better outcome at 1 year in patients with PCI within
30 days in GUSTO IV-ACS is in agreement with the results
of previous trials, demonstrating the benefits of an invasive
approach.26,27 However, the better prognosis of patients with
PCI in GUSTO IV-ACS may be caused by selection bias.
It has been suggested that the absence of treatment benefit with
abciximab might be related to selection of a low-risk patient
population. This contention clearly is not supported by our 1-year
observations. Overall mortality in GUSTO IV-ACS was 6.6% at 6
months and 8.3% at 1 year, which is comparable to that of the
PURSUIT (Platelet IIb/IIIa in Unstable angina: Receptor Suppres-
sion Using Integrilin Therapy) trial (5.8% at 6 months) and much
higher than the 1-year mortality in FRISC II (Fragmin and/or early
Revascularization during InStability in Coronary artery disease),
which was 2.2% in the invasive group and 3.9% in the noninvasive
group.26 In fact, the 1-year mortality rate in the present trial was
comparable to recent trials with fibrinolysis in patients with ST-
elevation myocardial infarction.28–30 This may imply that the
patients in the present trial consist of a relatively high-risk popula-
tion compared with other ACS trials.
Although overall cardiovascular risk in GUSTO IV-ACS
patients was not low, with a high proportion of ST-segment
depression (80%) or positive troponin (52%) at baseline and
a relatively high 1-year mortality, patients may still have been
enrolled with a false-positive diagnosis of ACS. For example,
positive troponin in GUSTO IV-ACS was allowed as a single
objective inclusion criterion in patients with chest pain, but
this may have been caused by renal failure, congestive heart
failure, hypertension, or liver disease in some of the patients.
Moreover, positive troponin may have been caused by an
infarct several days before admission, because troponin may
remain high for several days.
There were also differences between the ECG inclusion
criteria of GUSTO IV-ACS and previous trials. In GUSTO
IV-ACS, ECG ST depression had to be at least 0.5 mm,
compared with at least 1.0 mm in the PRISM and PRISM-
PLUS trials. Patients admitted with ACS with at least 0.5 mm
of ST depression have an increased risk of mortality and
infarction compared with patients with normal ECGs, al-
though the severity of the ST depression is strongly associ-
ated with a poor prognosis.31,32 However, ECGs with ST-
segment depression of 0.5 mm may have included
nonspecific abnormalities. It is therefore possible that a
proportion of the patients who were included in GUSTO
IV-ACS did not have a real ACS. This is particularly of
interest because an abnormal ECG was more often the reason
for inclusion in women than in men. Indeed, women in other
trials more often had nonsignificant coronary artery disease
than men,33 with a lack of treatment benefit. In fact, a
significantly increased risk of death and myocardial infarc-
tion at 30 days in women was also observed with GP IIb/IIIa
inhibitors in the recently published meta-analysis.10 However,
it is difficult to demonstrate whether different patients were
included in GUSTO IV-ACS because of the differences in
inclusion criteria between GUSTO IV-ACS and previous
trials and whether this may have influenced results. Head-to-
TABLE 2. Clinical End Points
Characteristic
Placebo
(n2598)
24-h Abciximab
(n2590)
48-h Abciximab
(n2612)
30 Days
Death 102 (3.9) 88 (3.4) 111 (4.3)
MI 133 (5.1) 146 (5.6) 153 (5.9)
Death or MI 209 (8.0) 212 (8.2) 238 (9.1)
30 Days to 1 year
Death 101 (4.0) 124 (5.0) 123 (4.9)
1 Year
Death 203 (7.8) 212 (8.2) 234 (9.0)
Values are n (%). There were no statistically significant differences.
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head comparisons are needed between the different GP
IIb/IIIa inhibitors to guide medication choice.
Conclusions
GUSTO IV-ACS demonstrated that patients with ACS with
ST depression and/or elevated troponin who were not sched-
uled to undergo early coronary revascularization while taking
the study drug had a relatively high 1-year mortality. Tropo-
nin and CRP had additive value in predicting 1-year mortal-
ity. Compared with placebo, abciximab did not provide any
survival benefit at 1 year. Patients without troponin elevation
tended to do worse with abciximab, which is consistent with
findings in other GP IIb/IIIa inhibitors.10 Those with CRP
elevation also tended to do worse with abciximab, and this
may represent a different pathophysiological mechanism that
should be explored. The percentage of patients with early
revascularization while taking study drug in GUSTO IV-ACS
was very low, which may have contributed to the lack of
benefit of abciximab. In patients with documented ACS,
abciximab should be reserved for those patients undergoing
PCI or who do not respond to medical therapy and in whom
a PCI is planned within 24 hours.
Acknowledgments
This study was supported by Centocor Inc, Malvern, Pa. Full
independence of the analyses and control over publication remain
with the authors, along with the responsibility for any errors.
References
1. Yeghiazarians Y, Braunstein JB, Askari A, et al. Unstable angina
pectoris. N Engl J Med. 2000;342:101–114.
2. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute
coronary syndromes: acute coronary syndromes without persistent ST
segment elevation. Eur Heart J. 2000;21:1406–1432.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for
the management of patients with unstable angina and non–ST-segment
elevation myocardial infarction: executive summary and recommen-
dations. Circulation. 2000;102:1193–1209.
4. Yusuf S, Zhao F, Mehta SR, et al, for the Clopidogrel in Unstable Angina
to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in
addition to aspirin in patients with acute coronary syndromes without
ST-segment elevation. N Engl J Med. 2001;345:494–502.
5. CAPTURE Investigators. Randomised placebo-controlled trial of
abciximab before and during coronary intervention in refractory unstable
angina: the CAPTURE study. Lancet. 1997;349:1429–1435.
6. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa
with eptifibatide in patients with acute coronary syndromes. N Engl
J Med. 1998;339:436–443.
7. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa
receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction:
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients
Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
N Engl J Med. 1998;338:1488–1497.
8. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor
blocker abciximab on outcome in patients with acute coronary syndromes
without early coronary revascularisation: the GUSTO IV-ACS ran-
domised trial. Lancet. 2001;357:1899–1900.
9. PARAGON Investigators. International, randomized, controlled trial of
lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in
unstable angina. Circulation. 1998;97:2386–2395.
10. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa
inhibitors in acute coronary syndromes: a meta-analysis of all randomised clinical
trials that enrolled over 1000 patients. Lancet. 2002;359:189–198.
11. Kaplan El, Meier P. Nonparametric estimation from incomplete obser-
vations. J Am Stat Assoc. 1958;53:457–481.
12. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit
with abciximab in patients undergoing percutaneous coronary inter-
vention. J Am Coll Cardiol. 2001;37:2059–2065.
13. Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in
acute coronary syndromes: an economic analysis of Western European patients
enrolled in the PURSUIT trial. Eur Heart J. 2002;23:50–58.
14. Leebeek FW, Boersma E, Cannon CP, et al. Oral glycoprotein IIb/IIIa
receptor inhibitors in patients with cardiovascular disease: why were the
results so unfavorable. Eur Heart J. 2002;23:444–457.
15. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors:
recognition of a two-edged sword? Circulation. 2002;106:379–385.
16. Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocyte-platelet aggregation,
platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutane-
ous coronary intervention: effects of dalteparin or unfractionated heparin in
combination with abciximab. Am Heart J. 2001;142:790–798.
17. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the
rise in levels of circulating inflammatory markers after percutaneous
coronary revascularization. Circulation. 2001;104:163–167.
18. Fredrickson BJ, Turner NA, Kleiman NS, et al. Effects of abciximab,
ticlopidine, and combined abciximab/ticlopidine therapy on platelet and
leukocyte function in patients undergoing coronary angioplasty. Circu-
lation. 2000;101:1122–1129.
19. Cohen M. Glycoprotein IIb/IIIa receptor blockers in acute coronary syn-
dromes: GUSTO IV-ACS. Lancet. 2001;357:1899–1900.
20. EPIC Investigators. Use of a monoclonal antibody directed against the
platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
N Engl J Med. 1994;330:956–961.
21. EPILOG Investigators. Platelet IIb/IIIa receptor blockade and low-dose
heparin during percutaneous coronary revascularization. N Engl J Med.
1997;336:1689–1696.
22. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic
implications of platelet glycoprotein IIb/IIIa blockade in patients
undergoing coronary stenting: results from a multicentre randomised trial:
EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitor for
Stenting. Lancet. 1999;354:2019–2024.
23. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa
blockade with tirofiban on adverse cardiac events in patients with
unstable angina or acute myocardial infarction undergoing coronary
angioplasty. Circulation. 1997;96:1445–1453.
24. IMPACT-II Investigators. Randomised placebo-controlled trial of effect
of eptifibatide on complications of percutaneous coronary intervention:
IMPACT-II. Lancet. 1997;349:1422–1428.
25. O’Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet
glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent
intervention. JAMA. 2002;287:618–621.
26. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an
invasive compared with a non-invasive strategy in unstable coronary-
artery disease: the FRISC II invasive randomised trial. FRISC II Inves-
tigators: Fast Revascularisation during Instability in Coronary artery
disease. Lancet. 2000;356:9–16.
27. Cannon C. Tactics-TIMI 18 (Treat angina with Aggrastat and determine
Cost of Therapy with an Invasive or Conservative Strategy). N Engl
J Med. 2001;344:1879–1887.
28. Califf RM, White HD, van de Werf F, et al. One-year results from the
Global Utilization of Streptokinase and TPA for Occluded Coronary
Arteries (GUSTO-I) trial. Circulation. 1996;94:1233–1238.
29. Topol EJ, Ohman EM, Armstrong PW, et al. Survival outcomes 1 year
after reperfusion therapy with either alteplase or reteplase for acute
myocardial infarction: results from the Global Utilization of Strep-
tokinase and t-PA for Occluded Coronary Arteries (GUSTO) III trial.
Circulation. 2000;102:1761–1765.
30. Fu Y, Goodman S, Chang WC, et al. Time to treatment influences the
impact of ST-segment resolution on one-year prognosis: insights from the
assessment of the safety and efficacy of a new thrombolytic (ASSENT-2)
trial. Circulation. 2001;104:2653–2659.
31. Hyde TA, French JK, Wong CK, et al. Four-year survival of patients with acute
coronary syndromes without ST-segment elevation and prognostic significance
of 0.5-mm ST-segment depression. Am J Cardiol. 1999;84:379–385.
32. Kaul P, Fu Y, Chang WC, et al. Prognostic value of ST segment
depression in acute coronary syndromes: insights from PARAGON-A
applied to GUSTO-IIb: PARAGON-A and GUSTO IIb Investigators:
Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organi-
zation Network. J Am Coll Cardiol. 2001;38:64–71.
33. Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic
profile of patients presenting with acute coronary syndromes who do not
have significantly coronary artery disease: the Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT)
Trial Investigators. Circulation. 2000;102:1101–1106.
442 Circulation January 28, 2003
